Search results

Evidence-based recommendations on UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia

Type

Medical technologies guidance

Published

04 May 2021

Evidence-based recommendations on HeartFlow FFRCT for estimating fractional flow reserve from coronary CT angiography

Type

Medical technologies guidance

Last updated

19 May 2021

Evidence-based recommendations on Parafricta Bootees and Undergarments to reduce skin breakdown in people with or at risk of pressure ulcers

Type

Medical technologies guidance

Last updated

19 May 2021

Evidence-based recommendations on Danis stent for acute oesophageal variceal bleeding

Type

Medical technologies guidance

Published

31 March 2021

Evidence-based recommendations on avelumab (Bavencio) for metastatic Merkel cell carcinoma in adults

Type

Technology appraisal guidance

Last updated

21 April 2021

Evidence-based recommendations on selective internal radiation therapies SIR-Spheres (Sirtex), TheraSphere (BTG) and QuiremSphere (Quirem Medical) for treating

Type

Technology appraisal guidance

Published

31 March 2021

Evidence-based recommendations on anakinra (Kineret) for treating adult-onset Still’s disease and systemic juvenile idiopathic arthritis in people 8 months and

Type

Technology appraisal guidance

Published

31 March 2021

NICE is unable to make a recommendation on blinatumomab (Blincyto) for previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia in

Type

Technology appraisal guidance

Published

31 March 2021

Evidence-based recommendations on ribociclib (Kisqali) for treating hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally

Type

Technology appraisal guidance

Published

31 March 2021

Evidence-based recommendations on bempedoic acid with ezetimibe (Nilemdo and Nustendi) for treating primary hypercholesterolaemia or mixed dyslipidaemia as an

Type

Technology appraisal guidance

Published

28 April 2021

Evidence-based recommendations on acalabrutinib (Calquence) for treating chronic lymphocytic leukaemia in adults

Type

Technology appraisal guidance

Published

21 April 2021

Evidence-based recommendations on avelumab (Bavencio) for untreated metastatic Merkel cell carcinoma in adults

Type

Technology appraisal guidance

Published

21 April 2021

Evidence-based recommendations on tafamidis (Vyndaqel) for treating transthyretin amyloidosis with cardiomyopathy in adults

Type

Technology appraisal guidance

Published

12 May 2021

Evidence-based recommendations on andexanet alfa (Ondexxya) for reversing anticoagulation form apixaban or rivaroxaban in adults with life-threatening or uncont

Type

Technology appraisal guidance

Published

12 May 2021

Evidence-based recommendations on carfilzomib (Kyprolis) with dexamethasone and lenalidomide (Revlimid) for previously treated multiple myeloma in adults

Type

Technology appraisal guidance

Published

28 April 2021

Evidence-based recommendations on pembrolizumab (Keytruda) for treating locally advanced or metastatic urothelial carcinoma after platinum

Type

Technology appraisal guidance

Published

28 April 2021

Evidence-based recommendations on olaparib (Lynparza) plus bevacizumab (Avastin) for maintenance treatment of advanced ovarian, fallopian tube or primary perito

Type

Technology appraisal guidance

Published

28 April 2021

NICE is unable to make a recommendation on selinexor with low-dose dexamethasone for treating refractory multiple myeloma in adults because Karyopharm

Type

Technology appraisal guidance

Published

19 May 2021

Evidence-based recommendations on ravulizumab (Ultomiris) for treating paroxysmal nocturnal haemoglobinuria in adults

Type

Technology appraisal guidance

Published

19 May 2021

NICE is unable to make a recommendation on crisaborole for treating mild to moderate atopic dermatitis in people 2 years and older because Pfizer withdrew its

Type

Technology appraisal guidance

Published

19 May 2021

Evidence-based recommendations on ofatumumab (Kesimpta) for treating relapsing–remitting multiple sclerosis in adults with active disease defined by clinical or

Type

Technology appraisal guidance

Published

19 May 2021

NICE is unable to make a recommendation on teduglutide (Revestive) for short bowel syndrome in people 1 year and over because Takeda withdrew its evidence

Type

Technology appraisal guidance

Published

21 April 2021

Evidence-based recommendations on atezolizumab (Tecentriq) for treating advanced non-small-cell lung cancer in adults

Type

Technology appraisal guidance

Published

02 June 2021

NICE is unable to make a recommendation on ibrutinib (Imbruvica) with rituximab for untreated chronic lymphocytic leukaemia because Janssen did not provide an

Type

Technology appraisal guidance

Published

26 May 2021

NICE is unable to make a recommendation on ibrutinib (Imbruvica) with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma in

Type

Technology appraisal guidance

Published

26 May 2021

Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer in adults after 2 or more

Type

Technology appraisal guidance

Published

26 May 2021

Evidence-based recommendations on ozanimod (Zeposia) for treating relapsing–remitting multiple sclerosis in adults with clinical or imaging features of active

Type

Technology appraisal guidance

Published

09 June 2021

Evidence-based recommendations on Nivolumab (Opdivo) for previously treated unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma

Type

Technology appraisal guidance

Published

15 June 2021